**[Country Name]**

**YELLOW FEVER DIAGNOSTICS PROCUREMENT SUPPORT RENEWAL REQUEST FORM**

|  |
| --- |
| **This template is for countries requesting renewal of Gavi support for yellow fever diagnostics procurement. The following are mandatory requirements to be submitted alongside this request form:**   * Signatures required to endorse this request before submission to Gavi: * Director of Finance for Ministry of Health (or delegated authority). * Director of national yellow fever laboratory (or delegated authority). * Minister of Finance (or their delegated authorities) is recommended. * The Coordination Forum (ICC, HSCC or equivalent body) is recommended to endorse this request before submission to Gavi. This can be done also through the ICC/HSCC endorsement of the Joint Appraisal (JA) and should be reflected in ICC/HSCC minutes.   Yellow fever diagnostic procurement support is provided to allow more timely, reliable identification and laboratory confirmation of yellow fever cases for more rapid containment of outbreaks and better prioritisation of preventive yellow fever vaccination efforts. Specifically, this support is intended to assist countries’ efforts to follow World Health Organization (WHO) recommendations when conducting yellow fever diagnostic tests on all samples received from suspected yellow fever cases.  The request will be reviewed by High Level Review Panel members (HLRP) who will make a recommendation for renewal to Gavi’s CEO.  **Submit this request form and the aforementioned requirements through the YF diagnostics procurement support section of the portal** |
|  |

# Yellow fever laboratory supplies and equipment

## Routine testing: Number of samples from suspected yellow fever cases tested or expected to be tested in 2020

*Complete the table below with details of your country’s* ***routine yellow fever testing******activities*** *in 2020*

| **Yellow fever Routine Testing** | **January to June 2020** | **Expected during July to December 2020** |
| --- | --- | --- |
| Number of samples received or expected to receive for testing |  |  |
| Number of reagent bundles ordered or expected to be ordered from UNICEF Supply Division |  |  |
| Number of samples tested or expected to be tested using serologic methods, for example, ELISA |  |  |
| Number of samples tested or expect to test using molecular methods, for example, PCR |  |  |

## Outbreak response testing: Number of samples from suspected yellow fever cases tested or expected to be tested in 2020

*Complete the table below with details of your country’s* ***yellow fever outbreak response testing activities*** *in 2020*

| **Yellow fever outbreak response testing** | **January to June 2020** | **Expected during July to December 2020** |
| --- | --- | --- |
| Number of samples received or expected to receive for testing |  |  |
| Number of reagent bundles ordered or expected to be ordered from UNICEF Supply Division |  |  |
| Number of samples tested or expected to be tested using serologic methods, for example, ELISA |  |  |
| Number of samples tested or expect to test using molecular methods, for example, PCR |  |  |

## Number of samples from suspected yellow fever cases expected to be tested in 2021

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| |  |  | | --- | --- | | Number of samples expected to undergo serology testing in 2021[[1]](#footnote-2) |  | | |  |
| Number of samples expected to undergo PCR testing in 2021[[2]](#footnote-3) |  |

## Equipment and other laboratory supplies

*Equipment: Complete verify accuracy of information provided in the table below with information on yellow fever laboratory equipment approved in* ***2020 and requested for 2021***

|  |  |  |
| --- | --- | --- |
|  | **Amount of equipment approved by Gavi in 2020** | **Amount of equipment requested for 2021[[3]](#footnote-4)** |
| Elisa Reader |  |  |
| Elisa Washer |  |  |
| PCR Machine |  |  |
| Biosafety Cabinet |  |  |

*Laboratory Personal Protective Equipment (PPE): Complete and verify accuracy of information provided in the table below with information on PPE for yellow fever testing approved in* ***2020 and requested for 2021***

|  |  |  |
| --- | --- | --- |
|  | **Amount of laboratory PPE approved by Gavi in 2020** | **Amount of laboratory PPE requested for 2021[[4]](#footnote-5)** |
| PPE – laboratory coats |  |  |
| PPE – surgical masks |  |  |
| PPE - goggles |  |  |
| PPE – disposable gloves |  |  |

## Strategic considerations

### 1.5.1. **Rationale for the request**

Briefly describe how yellow fever diagnostic capacity fits into your country’s plan for eliminating yellow fever epidemics.

|  |
| --- |
|  |

### 1.5.2. Recent laboratory improvement activities

Briefly describe improvements (achieved, in progress or planned) and progress made to address the gaps and other findings from the 2018 Gavi-funded YF laboratory capacity assessment report or latest WHO YF laboratory capacity assessments

|  |
| --- |
|  |

## Financial sustainability and budgeting of yellow fever laboratory

*\*A cost sharing requirement will eventually be introduced for yellow fever materials. This cost-sharing will not come into effect through at least the end of 2021. More information will be provided by your Gavi Senior Country Manager (SCM) as it becomes available. \**

Outline any changes, either expected or since the initial application for yellow fever diagnostics support, in domestic budget for yellow fever laboratory capacity needs, including yellow fever laboratory supplies and equipment.

|  |
| --- |
|  |

#### Comments

Please provide any comments you have about this renewal application and how to improve it

|  |
| --- |
|  |

|  |  |
| --- | --- |
| Director of Finance for Ministry of Health (or delegated authority) | Director of national yellow fever laboratory (or delegated authority) |
| Name: | Name: |
| Date: | Date: |
| Signature: | Signature: |

1. Number of samples expected to undergo ELISA testing in 2021 may be estimated based on samples received (or expected to receive) in 2020. Alternatively, the equivalent to the largest number of samples received for testing in a single year over the last three years, excluding years with yellow fever outbreaks, can be used. For example, if no outbreaks occurred in 2017, 2018, and 2019 and more samples were received for testing in 2018 than in 2017 or 2019, the number of samples expected to be tested in 2021 can be estimated to be the same as the number of samples received for testing in 2018. If an outbreak occurred in 2018 and more samples were received for testing in 2019 than 2017, then the number of samples expected to be tested in 2021 can be estimated to be the same as the number of samples received for testing in 2019. Alternative approaches can be used if justification is provided. [↑](#footnote-ref-2)
2. If capacity to test for yellow fever with PCR is available, the number of samples expected to undergo PCR testing in 2021 may be estimated to be equivalent to the number of samples tested or expected to be tested with PCR in 2020 or the largest number of samples collected ≤10 days after onset of illness and received for testing in a single year over the last three years, excluding years with yellow fever outbreaks. For example, if no outbreaks occurred in 2017, 2018, and 2019 and more samples collected ≤10 days after onset of illness were received for testing in 2018 than in 2017 or 2019, the number of tests expected to be run in 2021 can be estimated to be the same as the number of samples collected ≤10 days after onset of illness and received for testing in 2018. If an outbreak occurred in 2018 and more samples collected ≤10 days after onset of illness were received for testing in 2019 than 2017, then the number of samples expected to be tested in 2021 can be estimated to be the same as the number of samples collected ≤10 days after onset of illness and received for testing in 2019. Alternative approaches can be used if justification is provided. [↑](#footnote-ref-3)
3. Only equipment not previously approved by Gavi will be considered. Requests for additional equipment beyond what has been approved in 2020 will be rejected, except where extremely strong rationale is provided in comments section below. [↑](#footnote-ref-4)
4. Should generally be estimated to be the same as for 2020. If different amount needed for yellow fever testing, please provide rationale in comments section below. [↑](#footnote-ref-5)